A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'

drug protocol number
D589SC00003
drug sponsor
AstraZeneca
drug study
Budesonide + Formoterol VS. Budesonide + Terbutaline
drug trial site
AFH-DH
drug status
Completed
drug phase